Portuguese Society of Metabolic Diseases Partners with Bentham Science Journals
News release date: February 02, 2022
Bentham Science has signed partnership with the Portuguese Society of Metabolic Diseases for its high impact journals, Current Drug Metabolism (JCR IF: 3.731), Endocrine, Metabolic & Immune Disorders – Drug Targets (JCR IF: 2.895) and Drug Metabolism Letters. This partnership enables members of the society to publish their research in these journals with a considerable discount on Gold Open Access. The members also get the opportunity to avail concession in the charges on personal subscription for the journals.
Portuguese Society of Metabolic Disorders (SPDM), founded in 2002, is a scientific society whose main goal is to bring together professionals from different fields under the scope of inborn errors of metabolism (IEM). SPDM aims to promote awareness of IEM, implementing early diagnosis and therapy in order to increase the quality of life and social integration of all patients.
SPDM encourages scientific research, development of diagnosis and therapeutic protocols and organizes regular clinical and laboratory meetings, pre and postgraduate courses, as well as an annual International Symposium. SPDM promotes and supports the training of professionals in the field of IEM, awarding several scholarships and grants. For more information, please visit: https://www.spdm.org.pt/
Bentham Science Publishers is a major international science, technology, and medical publisher, providing academic researchers and industrial professionals with the latest information in diverse fields of science and technology. Our peer-reviewed scholarly journals and books have an ever-increasing readership of millions of researchers worldwide. Bentham Science journals are indexed in recognized indexing agencies and Information on our journals’ indexation, by various indexing agencies, can be viewed at https://benthamscience.com/index.php.
About the Journals:
Current Drug Metabolism (JCR IF: 3.73)
Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism, pharmacokinetics, and drug disposition. The journal serves as an international forum for the publication of full-length/mini review, research articles and guest edited issues in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the most important developments. The journal covers the following general topic areas: pharmaceutics, pharmacokinetics, toxicology, and most importantly drug metabolism.
To learn more, please visit the website: https://benthamscience.com/journals/current-drug-metabolism/
Endocrine, Metabolic & Immune Disorders - Drug Targets (JCR IF: 2.89)
This journal is devoted to full-length/ mini reviews and original articles of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders. Specific emphasis is placed on humoral and cellular targets for natural, synthetic, and genetically engineered drugs that enhance or impair endocrine, metabolic, and immune parameters and functions. Moreover, the topics related to the effects of food components and/or nutraceuticals on the endocrine-metabolic-immune axis and on microbiota composition are welcome.
To learn more, please visit the website: https://benthamscience.com/journals/endocrine-metabolic-and-immune-disorders-drug-targets/
Drug Metabolism Letters
Drug Metabolism Letters publishes letters, original research articles, mini-reviews, thematic issues based on mini-reviews and letters, commentaries, technical notes and drug clinical trial studies on major advances in all areas of drug metabolism and disposition.
In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; bioactivation; recent developments for the identification of drug metabolites, reactive intermediate and glutathione conjugates.
To learn more, please visit the website: https://benthamscience.com/journals/drug-metabolism-letters/